BYSI - Rasio rega marang prakiraan pendapatan BeyondSpring

BeyondSpring Inc. (BYSI) transitioned to a virtual model by outsourcing all testing, which triggered growth, and the forward P/S trajectory confirms this momentum. The 37.40 mark serves as a key metric for the current valuation. This trend reflects physicians' confidence in immune protection during therapy and management's commitment to ensuring global access to new medications.

BeyondSpring, Inc. - Prakiraan rega marang pendapatan BYSI (periode 04.07.2022 - 30.09.2025)

Rincian metrik komprehensif lan analitis BeyondSpring Inc (BYSI)

- rega pasar lan target rega analis:

Bagan rega BeyondSpring|BYSI - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar BeyondSpring Inc|BYSI - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham BeyondSpring|BYSI - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih beyondspringpharma.com|BYSI - Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas BeyondSpring Inc.|BYSI - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas BeyondSpring Inc.|BYSI - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku BeyondSpring Inc|BYSI - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BeyondSpring|Likuiditas cepet beyondspringpharma.com

- rincian asil keuangan lan kelipatan valuasi:

BYSI - Bathi pungkasan|Proyeksi bathi mangsa ngarep BeyondSpring Inc.|BYSI - Pangali P/E|Rega marang bathi mangsa ngarep BeyondSpring Pharma|BYSI - Rasio kapitalisasi marang bathi lan wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BeyondSpring Inc|BYSI - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) BeyondSpring|BYSI - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan beyondspringpharma.com|BYSI - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep BeyondSpring Inc.

- data pendapatan lan penerimaan dodolan:

BYSI - Total pendapatan perusahaan|Prakiraan pendapatan perusahaan BeyondSpring|BYSI - Rega marang dodolan|Rasio rega marang prakiraan pendapatan BeyondSpring Inc

Analisis umum perusahaan:BeyondSpring BYSI

Produk sing diprodhuksi beyondspringpharma.com

Investors assess the operational strength of assets through the ratio of market capitalization to expected sales, where the forward price-to-sales valuation trend reflects a real-time market reassessment of the business potential. For BeyondSpring Inc. (BYSI), the stability of its research staff minimizes operational risks, turning this indicator into a precise tool for analyzing the company's fundamental resilience as it reaches key development milestones.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte INCY|Hutchison MediPharma - Rasio rega marang prakiraan pendapatan|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One Biopharmaceuticals Inc|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan inhibrx.com INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharma FENC|Multiplikator forward rega marang pendapatan HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (corbuspharma.com)|Cardiff Oncology Corp - Multiplikator Forward P/S|Rega forward marang dodolan BCAB (BioAtla, Inc.)|LIXT: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Citius Pharmaceuticals, Inc. (CTXR)|Rasio rega marang prakiraan pendapatan Cellectar Biosciences|BLRX: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S aprea.com (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep chimerix.com|CYCC: Multiplikator Forward P/S|GTHX (G1 Therapeutics) - Rasio rega marang prakiraan pendapatan|KRON (Kronos Bio Corp) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kintara Pharma KTRA|Multiplikator forward rega marang pendapatan ONCT (Oncternal Therapeutics)|PRTG - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep